Placebo (0.9% normal saline)

BIOLOGICAL5 trials

Sponsors

University of Wisconsin, Madison, CSL Behring, Sanofi Pasteur, a Sanofi Company, Beijing Anzhen Hospital

Conditions

Acute Ischemic StrokeBurnCOVID-19COVID-19 (Healthy Volunteers)Healthy

Phase 1

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

CompletedNCT01542619

CSL BehringHealthy

Start: 2012-03-31End: 2012-07-31Updated: 2017-04-21

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

CompletedNCT04537208

Sanofi Pasteur, a Sanofi CompanyCOVID-19 (Healthy Volunteers)

Start: 2020-09-03End: 2021-11-19Updated: 2025-09-17

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

TerminatedNCT04798027

Sanofi Pasteur, a Sanofi CompanyCOVID-19

Start: 2021-03-12End: 2022-06-27Updated: 2025-09-11

Phase 4

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

RecruitingNCT07290751

Beijing Anzhen HospitalAcute Ischemic Stroke

Start: 2025-11-11End: 2026-12-31Target: 976Updated: 2025-12-23

Unknown Phase

Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes

CompletedNCT00585325

University of Wisconsin, MadisonBurn

Start: 2004-10-31End: 2008-11-30Updated: 2018-03-07

Related Papers

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.

2022-01-2559 citations

Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate

Clinical & Translational Immunology2022-01-0125 citations

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.

2021-04-19100 citations